{{Rsnum
|rsid=12479919
|Gene=SLC23A2
|Chromosome=20
|position=5000094
|Orientation=plus
|GMAF=0.2971
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=LOC102724905,SLC23A2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 43.8 | 45.3 | 10.9
| HCB | 45.5 | 50.0 | 4.5
| JPT | 48.9 | 44.4 | 6.7
| YRI | 84.1 | 14.3 | 1.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 45.5 | 50.0 | 4.5
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|19243932|OA=1
}} [[rs12479919]](A;A) genotype had a 41% lower risk of [[gastric cancer]] (OR)=0.59, 95% confidence interval (CI): 0.36-0.95; P trend=0.06

{{PMID Auto
|PMID=19252927
|Title=Bladder cancer SNP panel predicts susceptibility and survival.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}